Clinical Trial

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors. Drugs used in chemotherapy, such as temozolomide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether temozolomide is more effective with or without capecitabine in treating patients with advanced pancreatic neuroendocrine tumors.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2013-04-02; most recent amendment 2026-02-06.
Status change: Recruiting → Active, Not Recruiting 2016-03-08
Status change: Not Yet Recruiting → Recruiting 2014-02-04
Trial Details
NCT Number NCT01824875
Lead Sponsor ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Conditions Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
Enrollment 144 participants
Start Date 2013-08-08
Primary Completion 2021-05-26 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-25